Sanofi-Aventis To Work With Chinese Experts In Cancer Stem-Cell Research
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sanofi-Aventis will expand its footprint in China by collaborating with Tianjin's Institute of Hematology and Blood Diseases Hospital (IHBDH) in the field of cancer stem cells, the French drug maker announced Sept. 14
You may also be interested in...
Sea Change In China’s Anti-Cancer Market Shares
China's hospitals are increasingly turning to alkaloid products such as paclitaxel and docetaxel to treat cancer while immunostimulant anti-cancer products see a decline in use, despite owning the largest market share
Sea Change In China’s Anti-Cancer Market Shares
China's hospitals are increasingly turning to alkaloid products such as paclitaxel and docetaxel to treat cancer while immunostimulant anti-cancer products see a decline in use, despite owning the largest market share
Sanofi-Aventis Expands R&D Presence In China
SHANGHAI - Sanofi-Aventis recently expanded its R&D presence in China to meet the rapid growth of clinical programs and broaden its activities from drug-target identification to late-stage clinical studies